Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 26Genitourinary 4Head & Neck 3Gynecologic 2

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Cervical Esophagus Adenocarcinoma 1

Interventions

Paclitaxel 77pembrolizumab 59Carboplatin 57Bevacizumab 57Specimen Handling 48Magnetic Resonance Spectroscopy 39Cisplatin 32olaparib 31Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 19Topotecan 17Nivolumab 17Cyclophosphamide 16Immunoglobulin G 15Doxorubicin 15Disulfides 15niraparib 12fludarabine 12Surveys and Questionnaires 12Letrozole 12lenvatinib 11durvalumab 11atezolizumab 11Fulvestrant 10Drug Therapy 10abemaciclib 9Docetaxel 9Brachytherapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
dehydroftorafur × Gynecologic × 90 days × Clear all
NCT05564377 2026-06-12

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04615013 2026-04-16

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
GastrointestinalGynecologic

Cervical Esophagus Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡